(3D) Ultrasound Imaging Liver and Kidney

Launched by WESTERN UNIVERSITY, CANADA · Feb 14, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the use of a new imaging technique called 3D ultrasound during treatment for liver or kidney tumors. The goal is to see if using 3D ultrasound can improve the accuracy of procedures like ablation (which destroys cancer cells) or biopsies (which take samples of tissue to check for cancer). Unlike regular 2D ultrasound, which shows a flat image, 3D ultrasound creates a detailed three-dimensional view of the tumor, allowing doctors to see it from different angles and ensure it is properly treated. This method is safe, quick, and does not involve any invasive procedures.

To be eligible for this trial, patients should be between the ages of 65 and 74 and must be scheduled for standard care procedures for liver or kidney tumors. There are no specific exclusions, so most patients who meet the age requirement and are undergoing these treatments can participate. If you join the trial, you will have your ultrasound images compared to CT scans taken before and after the procedure to check that the tumors were completely removed or accurately targeted. This study aims to enhance treatment outcomes and ensure better monitoring of liver and kidney cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Patients who are scheduled for standard care liver or kidney ablation or biopsy
• Exclusion Criteria:
• • None